Table VI.
Comparison of the incidence of adverse reactions after treatment in the three groups of patients [n (%)].
| Adverse reactions | Rituximab group (n=79) | Cyclophosphamide group (n=86) | Combined therapy group (n=84) | χ2 test | P-value |
|---|---|---|---|---|---|
| Dizziness or headache | 8 (10.13) | 12 (13.95) | 5 (5.95) | 3.013 | 0.222 |
| Vomit | 12 (15.19) | 15 (17.44) | 6 (7.14) | 4.298 | 0.117 |
| Liver and kidney dysfunction | 2 (2.53) | 5 (5.81) | 1 (1.19) | 3.094 | 0.213 |
| Lung infection | 1 (1.27) | 3 (3.49) | 0 (0.00) | 3.356 | 0.187 |
| Incidence of adverse reactions | 23 (29.11) | 35 (40.70) | 12 (14.29) | 14.730 | <0.001 |